Drug Safety

, Volume 23, Issue 2, pp 143–164 | Cite as

Drug-Induced Respiratory Disorders

Incidence, Prevention and Management
  • Liubov (Louba) Ben-Noun
Review Article


Various drugs are associated with adverse respiratory disorders (ARDs) ranging in severity from mild, moderate to severe and even fatal. Cardioselective and nonselective β-blockers, calcium antagonists and dipyridamole can induce asthma. ACE inhibitors are mainly associated with cough. Amiodarone is related to a form of interstitial pneumonitis (IP) which can be fatal, tocainidine and flecainidine to a form of IP, and hydrochlorothiazide to a form of IP and pulmonary oedema. Antiasthmatic drugs can be associated with a paradoxical bronchospasm, while leukotriene antagonists are linked to the development of Churg-Strauss syndrome. Nonsteroidal anti-inflammatory drugs including aspirin (acetylsalicylic acid) may induce asthma. Gold is mainly related to IP, penicillamine to IP, systemic lupus erythematosus, bronchiolitis obliterans, and Goodpasture’s syndrome.

Acute respiratory reactions to nitrofurantoin include dyspnoea, cough, IP, and pleural effusion while IP and fibrosis are common in chronic reactions. Other antibacterials mainly evoke pneumonitis, pulmonary infiltrates and eosinophilia, and bronchiolitis obliterans. ARDs are similar for most categories of cytotoxic agents, with chronic pneumonitis and fibrosis being the most common. Noncardiogenic pulmonary oedema occurs as the most common respiratory complication in opioid agonist addiction. Psychotropic drugs such as phenothiazides, butyrophenones and tricyclic antidepressants can also induce pulmonary oedema. Oral contraceptives may produce asthma exacerbation, while long termuse and/or high doses of postmenopausal hormone replacement therapy increase the risk of asthma. Bromocriptine is mainly associated with pleural effusion, while methysergide is usually associated with pleural effusion and fibrosis. Some anorectic agents have been linked to the development of primary pulmonary hypertension.

The possibility of the occurrence of ARDs should be taken into account in each individual patient. Although in most cases the adverse effects are unpredictable, they can be reduced to aminimumor prevented if some drugs are avoided or stopped in time.


Asthma Amiodarone Montelukast Sodium Cromoglycate Ipratropium Bromide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    McNeill RS. Effect of a beta-adrenergic blocking agent, propranolol, on asthmatics. Lancet 1964; II: 1101–2CrossRefGoogle Scholar
  2. 2.
    Tattersfield AE, Harrison RN. Effect of beta-blocker therapy on airway function. Drugs 1983; 25Suppl. 2: 227–31CrossRefGoogle Scholar
  3. 3.
    Lewis RV, Lofthouse C. Adverse reactions with beta-adrenoreceptor blocking drugs: an update [abstract]. Drug Saf 1993; 9: 272PubMedCrossRefGoogle Scholar
  4. 4.
    Dunn TL, Gerber MJ, Shen AS, et al. The effect of topical ophtalmic instillation of timolol and betaxol on lung function in asthmatic subjects. Am Rev Respir Dis 1986; 133: 264–8PubMedGoogle Scholar
  5. 5.
    Graft D, Fowles J, McCoy CE, et al. Detection of beta-blocker use in people with asthma. Ann Allergy 1992; 69: 449–53PubMedGoogle Scholar
  6. 6.
    Craig TJ. Drugs to be used with caution in patients with asthma. Am Fam Physician 1996; 54: 947–53PubMedGoogle Scholar
  7. 7.
    Odeh M, Oliven A, Bassaan H. Timolol eye-drop-induced fatal bronchospasm in an asthmatic patient. J Fam Pract 1991; 32: 97–8PubMedGoogle Scholar
  8. 8.
    Schoene RB, Abuan T, Ward RL, et al. Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. Am J Ophtalmol 1984 97: 86–92Google Scholar
  9. 9.
    Harris LS, Grenstein SH, Bloom AF. Respiratory difficulties with betaxolol [letter]. Am J Ophtalmol 1986; 102–274Google Scholar
  10. 10.
    Beta-adrenoreceptor-blocking agents. In: Reynolds JEF, editor. Martindale: the extra pharmacopoeia. 30th ed. London: The Pharmaceutical Press, 1993: 624Google Scholar
  11. 11.
    Perrone MH, Barrett JA. Preclinical pharmacology of celiprolol: a cardioselective β-adrenergic antagonists and mild vasodilator. Am Heart J 1991; 121: 677–83PubMedCrossRefGoogle Scholar
  12. 12.
    Lamon KD. Clinical safety and efficacy of celiprolol. Am Heart J 1991; 121: 683–7PubMedCrossRefGoogle Scholar
  13. 13.
    Riddel KG, Shanks RG, Brogden RN. Celiprolol: a preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. Drugs 1987; 34: 438–58CrossRefGoogle Scholar
  14. 14.
    Doshan HD, Brown R, Applin WJ, et al. Effects of high doses of celiprolol in asthmatic patients. J Cardiovas Pharmacol 1986; 8Suppl. 4: S109–S11CrossRefGoogle Scholar
  15. 15.
    Matthys H, Doshan HD, Ruhle KH. The bronchosparing effects of celiprolol, a new beta-1 alpha-2 receptor antagonist, on pulmonary function of propraolol sensitive asthmatics. J Clin Pharmacol 1985; 25: 354PubMedGoogle Scholar
  16. 16.
    Milne RJ, Buckley MMT. Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease. Drugs; 1991; 41: 941–69PubMedCrossRefGoogle Scholar
  17. 17.
    Austen KF, Orange RP. Bronchial asthma: the possible role of the chemical mediators of immediate hypersensitivity in the pathogenesis of subacute chronic disease. Am Rev Respir Dis 1975; 112: 423–36PubMedGoogle Scholar
  18. 18.
    Fleckenstein-Grun G, Fleckenstein A. CA dependent changes in coronary smooth muscle tone and the action of Ca compounds with special reference to Adalat. In: Lochner W, Braasch W, Kroberg G, editors. 2nd International Adalat Symposium. New York (NY): Springer Verlag, 1976: 66–75Google Scholar
  19. 19.
    Fish JE, Norman PS. Effects of the calcium channel blocker, verapamil, on the asthmatic airway responses to muscarinic, histaminergic, and allergic stimuli. Am Rev Respir Dis 1986; 133: 73–4Google Scholar
  20. 20.
    Setton I, Hirsh D, Pragier G, editors. Israel Drug Compendium: IDC 1995 Petach-Tikva, Israel: The Pharmaceutical Section Manufacturers Association of Israel, 1995: 387–9Google Scholar
  21. 21.
    Russi E, Danta I, Ahmed T. Comparative modification of antigen-induced bronchoconstriction by the calcium antagonists, nifedipine and verapamil. Chest 1985; 88: 74–8PubMedCrossRefGoogle Scholar
  22. 22.
    Patel KR, Shama AL, Kerr W. The effects of inhaled verapamil on allergen-induced bronchoconstriction. Clin Allergy 1983; 13: 119–22PubMedCrossRefGoogle Scholar
  23. 23.
    Ben-Noun L. Acute asthma associated with sustained-release verapamil. Ann Pharmacother 1997; 31: 593–5PubMedGoogle Scholar
  24. 24.
    Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988; 319: 1517–25PubMedCrossRefGoogle Scholar
  25. 25.
    Marre M, Hallab M, Billiard A, et al. Small doses of ramipril to reduce micro-albuminuria in diabetic patients with incipient nephropathy independently of blood pressure changes. J Cardiovasc Pharmacol 1991; 18Suppl. 2: 165–8Google Scholar
  26. 26.
    The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857–63Google Scholar
  27. 27.
    Cox JP, Duggan J, O’Boyle CA, et al. A double blind evaluation of captopril in elderly hypertensives. J Hypertens 1989; 7: 299–303PubMedCrossRefGoogle Scholar
  28. 28.
    Lacourciere Y, Poirier L, Provencher P, et al. Once vs twice daily administration of a fixed combination of captopril plus hydrochlorothiaside in essential hypertension: a double-blind crossover study in known responders to a standard combinations. Br J Clin Pharmacol 1991; 32: 115–9PubMedCrossRefGoogle Scholar
  29. 29.
    Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin converting enzyme inhibitor therapy: a review of literature and pathophysiology. Ann Intern Med 1992; 117: 234–42PubMedGoogle Scholar
  30. 30.
    Visser LE, Stricker BHCH, Van der Velden J, et al. Angiotensin converting inhibitor associated cough: a population based case-control study. J Clin Epidemiol 1995; 48: 851–7PubMedCrossRefGoogle Scholar
  31. 31.
    Visser LE, Vlug AE, Van der Lei J, et al. Cough due to ACE inhibitors: a case control study using automated general practice data. Eur J Clin Pharmacol 1996 49: 439–44PubMedCrossRefGoogle Scholar
  32. 32.
    Charlton V, Dolow S, Fidel J, et al. Reproducibility of angiotensin converting enzyme inhibitor induced cough: a double-blind randomised study. Br J Clin Pharmacol 1995 39: 125–9CrossRefGoogle Scholar
  33. 33.
    Lunde H, Hedner T, Samuelsson O, et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitor. BMJ 1994 308: 18–21PubMedCrossRefGoogle Scholar
  34. 34.
    Lefevre J, Poirier L, Lacourciere Y. Prospective trial on captopril-related cough. Ann Pharmacother 1992; 26: 161–4Google Scholar
  35. 35.
    Holzgreve H. Safety profile of the combination of verapamil and trandolapril. J Hypertens 1997; 15Suppl. 2: S51–S53Google Scholar
  36. 36.
    Dossegger L, Nielsen T, Preston C, et al. Heart failure therapy with cilazapril: an overview. J Cardiovasc Pharmacol 1994; 24Suppl 3: S28–S41Google Scholar
  37. 37.
    Rosenthal JR, Osowski U. Tolerability and efficacy of antihypertensive treatment with cilazapril in general practice. Cardiology 1996; 87: 54–9PubMedCrossRefGoogle Scholar
  38. 38.
    Szucs T, Scheeweiss A. Cilazapril: an overview of its efficacy and safety in hypertension. Cardiology 1992; 80: 34–41PubMedCrossRefGoogle Scholar
  39. 39.
    Kang PM, Landau AJ, Eberhardt RT, et al. Angiotensin II receptor antagonists: a new approach to blockage of the renin-angiotensin system. Am Heart J 1994 127: 1388–401PubMedCrossRefGoogle Scholar
  40. 40.
    Allen TL, Gora-Harper ML. Cromolyn sodium for ACE inhibitor-induced cough. Ann Pharmacother 1997; 31: 773–5PubMedGoogle Scholar
  41. 41.
    McEwan JR, Choudry NB, Fuller RW. The effects of sulindac on the abnormal cough reflex associated with dry cough. J Pharmacol Exp Ther 1990; 255: 161–4PubMedGoogle Scholar
  42. 42.
    Gilchrist NL, Richards AM, March R, et al. Effect of sulindac on ACE inhibitor induced cough: randomised placebo-controlled double blind cross-over study. J Hum Hypertens 1989; 3: 451–5PubMedGoogle Scholar
  43. 43.
    Fogari R, Zoppi A, Tettamanti F, et al. Effects of nifedipine and indomethacine on cough induced by angiotensin-converting enzyme inhibitors. J Cardiovas Pharmacol 1992 19: 670–3Google Scholar
  44. 44.
    Onson C. Delay in diagnosis and empiric treatment of angiotensin-converting enzyme inhibitor induced cough in office practice. Arch Fam Med 1995; 4: 525–8CrossRefGoogle Scholar
  45. 45.
    Pomari C, Turco P, Negro RD. Has theophylline a role in the cure and prevention of ACE-inhibitor related cough? Respiration 1989; 55: 119–21PubMedCrossRefGoogle Scholar
  46. 46.
    Cazzola M, Matera MG, Licardi G, et al. Theophylline in the inhibition of angiotensin-convertin enzyme inhibitor-induced cough. Respiration 1993 60: 212–5PubMedCrossRefGoogle Scholar
  47. 47.
    Aldis WL. Cromolyn for cough due to angiotensin-converting enzyme inhibitor therapy. Chest 1991; 100: 1741–2PubMedCrossRefGoogle Scholar
  48. 48.
    Jayasuria PH. Sodium cromoglycate for AC inhibitor cough. Med J Aust 1992; 156: 363–4Google Scholar
  49. 49.
    Hargreaves MR, Benson MK. Inhaled sodium cromoglycate in angiotensin converting enzyme inhibitor cough. Lancet 1995; 345: 13–6PubMedCrossRefGoogle Scholar
  50. 50.
    Martin WJ, Rosenow EC. Amiodarone pulmonary toxicity (part 1) Chest 1988; 93: 1067–75Google Scholar
  51. 51.
    Kennedy J Jr I. Clinical aspects of amiodarone pulmonary toxicity. Clin Chest Med 1990; 11: 119–29PubMedGoogle Scholar
  52. 52.
    Dean PJ, Groshart KD, Porterfield JG, et al. Amiodarone associated pulmonary toxicity. A clinical and pathological study of eleven cases. Am J Clin Pathol 1987 87: 7–13PubMedGoogle Scholar
  53. 53.
    Martin WJ. Mechanisms of amiodarone pulmonary toxicity. Clin Chest Med 1990; 11: 131–8PubMedGoogle Scholar
  54. 54.
    Dimopulou I, Marathias K, Daganou M, et al. Low-dose amiodarone-related complications after cardiac operations. J Thorac Cardiovasc Surg 1997; 114: 31–7CrossRefGoogle Scholar
  55. 55.
    Marchlinski FE, Gansler TS, Waxman HL, et al. Amiodarone pulmonary toxicity. Ann Intern Med 1982 1982; 97: 839–45Google Scholar
  56. 56.
    Rakita L, Sobol SM, Mostow N, et al. Amiodarone pulmonary toxicity. Am Heart J 1983 106: 906–14PubMedCrossRefGoogle Scholar
  57. 57.
    Greenspon A, Kidwell GA, Hurley W, et al. Amiodarone-related postoperative adult respiratory distress syndrome. Circulation 1991; 84Suppl III: S407–S415Google Scholar
  58. 58.
    Martin WJ, Rosenow EC. Amiodarone pulmonary toxicity. Recognition and pathogenesis (part 2). Chest 1988; 93: 1242–8PubMedCrossRefGoogle Scholar
  59. 59.
    Morady, Sauve MJ, Malone P, et al. Long-term efficacy and toxicity of high dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. Am J Cardiol 1983; 52: 975–9PubMedCrossRefGoogle Scholar
  60. 60.
    Heger JJ, Prystowsky EN, Jackman WM, et al. Amiodarone. Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia and fibrillation. N Engl J Med 1981 305: 539–45PubMedCrossRefGoogle Scholar
  61. 61.
    Totmensch HH, Siron M, Tupliski M, et al. Possible association of pneumonitis with amiodarone therapy. Am Heart J 1980; 100: 412–3CrossRefGoogle Scholar
  62. 62.
    VanZadiok N, Darmata JI, Diiren DR, et al. Amiodarone pneumonitis. Eur J Respir Dis 1983 64: 313–7Google Scholar
  63. 63.
    Heger JJ, Prystowsky EN, Ziper DP. Relationship between amiodarone dosage drug concentrations and adverse side effects. Am Heart J 1983; 106: 931–4PubMedCrossRefGoogle Scholar
  64. 64.
    Kowey PR, Friehling TD, Marinchak RA, et al. Safety and efficacy of amiodarone. The low-dose perspective. Chest 1988; 93: 54–5PubMedCrossRefGoogle Scholar
  65. 65.
    Zaher C, Hamer A, Peter I, et al. Low dose steroid therapy for prophylaxis of amiodarone-induced pulmonary infiltrates. N Engl J Med 1983 308: 779PubMedCrossRefGoogle Scholar
  66. 66.
    Horn HR, Hadidian Z, Johnson JL, et al. Safety evaluation of tocainide in the American emergency use program. Am Heart J 1980 100: 1037–40PubMedCrossRefGoogle Scholar
  67. 67.
    Holmes B, Heel RC. Flecainide: a preliminary report of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985; 29: 1–33PubMedCrossRefGoogle Scholar
  68. 68.
    Feinberg L, Travis WD, Ferrans V, et al. Pulmonary fibrosis associated with tocainide. Am Rev Respir Dis 1990 141: 505–8PubMedGoogle Scholar
  69. 69.
    Hanston P, Evrard P, Mahieu P, et al. Flecainide associated interstitial pneumonitis. Lancet 1991: 337: 371–2PubMedCrossRefGoogle Scholar
  70. 70.
    Akoun G, Cadranel JL, Israel-Biet D, et al. Flecainide-associated pneumonitis. Lancet 1991 49: 337: 49CrossRefGoogle Scholar
  71. 71.
    Ranhovsky A, Kempthorne-Rawson J. The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Circulation 1990; 81: 1205–9CrossRefGoogle Scholar
  72. 72.
    Simon RS, Baldwin JL. Drug-induced asthma. In: Bierman CW, Pearlman DS, Shapiro GG, editors. Allergy, Asthma, and Immunology from Infancy to Adulthood. 3rd ed. Philadelphia (PA): WB Saunders, 1996: 549–57Google Scholar
  73. 73.
    Biron P, Dessureault J, Napke E. Acute allergic interstitial pneumonitis induced by hydrochlorothiaside. Can Med Assoc J 1991; 145: 28–34Google Scholar
  74. 74.
    Kavaru MS, Ahmad M, Amirthalingam KN. Hydrochlorothiaside-induced acute pulmonary edema. Cleve Clin J Med 1990; 57: 181–4PubMedGoogle Scholar
  75. 75.
    Bell RT, Lippmann M. Hydrochlorothiazide-induced pulmonary edema. Arch Intern Med 1979; 139: 817–9PubMedCrossRefGoogle Scholar
  76. 76.
    Steinberg AD. Pulmonary edema following ingestion of hydrochlorothiazide. JAMA 1968; 204: 825–7PubMedCrossRefGoogle Scholar
  77. 77.
    Dorn MR, Walker BK. Noncardiogenic pulmonary edema associated with hydrochlorothiazide therapy. Chest 1981; 79: 484–3CrossRefGoogle Scholar
  78. 78.
    Weddington WW, Mulroy MF, Sandri SR. Pneumonitis and hydrochlorothiaside. Ann Intern Med 1973; 70: 293Google Scholar
  79. 79.
    Bianco S, Vaghi A, Robuschi M, et al. Prevention of exercise-induced bronchoconstriction by inhaled frusemide. Lancet 1988; II: 252–5CrossRefGoogle Scholar
  80. 80.
    Bianco S, Pieroni MG, Refini RM, et al. Protective effect of inhaled furosemide on allergen-induced early and late asthmatic reactions. N Engl J Med 1989 321: 1069–73PubMedCrossRefGoogle Scholar
  81. 81.
    Anonymous. Inhaled furosemide and asthma. Lancet 1990; 335: 944–6Google Scholar
  82. 82.
    Anderson SD, Wei HE, Temple DM, et al. Inhibition by furosemide of inflammatorymediators fromlung fragments. N Engl J Med 1991 324: 131PubMedGoogle Scholar
  83. 83.
    Lloyd EL. Frusemide and prevention of bronchoconstriction. Lancet 1988; II: 564CrossRefGoogle Scholar
  84. 84.
    Chung KF, Barnes PJ. Inhaled frusemide on bronchial responsiveness to methacholine. N Engl J Med 1990; 322: 935–6CrossRefGoogle Scholar
  85. 85.
    Flower RF, Moncada S, Vane JR. Drug therapy of inflammation. Analgesic antipyretics and anti-inflammatory agents; drugs employed in the treatment of gout. In: Gilman AG, Goodman LS, Rall TW, et al., editors. The pharmacological basis of therapeutics. 7th ed. New York (NY): MacMillan, 1985: 686–8Google Scholar
  86. 86.
    Falliers CJ. Aspirin and subtypes of asthma: risk factors. J Allergy 1973; 52: 141–7Google Scholar
  87. 87.
    Vedanthan PK, Menon MM, Bell TD, et all. Aspirin and tartrazine oral challenge: incidence of adverse response in chronic childhood asthma. J Allergy Clin Immunol 1977; 60: 8–13PubMedCrossRefGoogle Scholar
  88. 88.
    Rachelevsky GS, Coulson A, Siegel SC, et al. Aspirin intolerance in chronic asthma detected by oral challenge. Pediatrics 1975 56: 443–8Google Scholar
  89. 89.
    Szczeklik A, Grylewski RJ. Asthma and antiinflammatory drugs: mechanisms and clinical patterns. Drugs 1983; 25: 533–43PubMedCrossRefGoogle Scholar
  90. 90.
    VanLeeuwen WS. Pathognomonishe bedeutung der Uebermpfindlichkeit gegen Aspirin bei Asthmatikern. MunchMedWochenschr 1928; 75: 1588Google Scholar
  91. 91.
    McDonald JR, Mathison DA, Stevenson DD. Aspirin intolerance in asthma. J Allergy Clin Immunol 1972; 50: 198–207PubMedCrossRefGoogle Scholar
  92. 92.
    Farr RS. The need to re-evaluate acetylsalicylic acid (aspirin). J Allergy 1970; 45: 321–8PubMedCrossRefGoogle Scholar
  93. 93.
    Stenius BSM, Lemola M. Hypersensitivity to acetylsalicylic acid (ASA) and tartrazine in patients with asthma. ClinAllergy 1976; 6: 119–29Google Scholar
  94. 94.
    Farr RS, Spector SL, Wangaard C. Asthma and non-steroidal anti-inflammatory drugs. Ann Intern Med 1978; 89: 577–600PubMedGoogle Scholar
  95. 95.
    Samter M, Beers Jr RF. Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann Intern Med 1968; 68: 975–83PubMedGoogle Scholar
  96. 96.
    Lockey RF, Rucknagel DL, Vanselow NA. Familial occurrence of asthma, nasal polyposis and aspirin intolerance. Ann Intern Med 1973; 78: 57–63PubMedGoogle Scholar
  97. 97.
    Settipane GA, Puddupakkam RK. Aspirin intolerance III: subtypes, familial occurrence, and cross-reactivity with tartrazine. J Allergy Clin Immunol 1975; 56: 215–21PubMedCrossRefGoogle Scholar
  98. 98.
    Dahlen BM, Kumlin DM, Margolskee C, et al. The leukotriene receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine aspirin in aspirin-sensitive asthmatics. Eur Respir J 1993; 6: 1018–26PubMedGoogle Scholar
  99. 99.
    Lee TH. Mechanisms of bronchospasm in aspirin-sensitive asthma. Am Rev Respir Dis 1993; 148: 1442–3PubMedCrossRefGoogle Scholar
  100. 100.
    Szczeklik A, Gryglewski RJ, Czerniavska-Mysik G, et al. Aspirin induced asthma: hypersensitivity to fenoprofen and ibuprofen in relation to their inhibitory action to prostaglandin generation by different microsomal enzymic preparations. J Allergy Clin Immunol 1976; 58: 10–8PubMedCrossRefGoogle Scholar
  101. 101.
    Santiago Jr SM. Acute respiratory failure secondary to indomethacin in an aspirin intolerant asthmatic patient. Ann Allergy 1976; 37: 138–41PubMedGoogle Scholar
  102. 102.
    Polachek J, Shvartzman P. Acute bronchial asthma associated with the administration of ophtalmic indomethacin Isr J Med Sci 1996; 32: 1107–9PubMedGoogle Scholar
  103. 103.
    Sitenga GL, Yong ER, Van Dellen RG, et al. Asthma caused by topical application of ketorolac. Ophtalmology 1996; 103: 890–2Google Scholar
  104. 104.
    Goldin J, Hayhurst M, Potgieter PD. Severe asthma due to intravenous avapyrazone and dipyrone [letter]. S Afr Med J 1986; 69: 162PubMedGoogle Scholar
  105. 105.
    Timperman JA. A fatal asthmatic attack following administration of an indomethacin suppository. J Forensic Med 1971; 98: 30–2Google Scholar
  106. 106.
    Herbert WG, Scopelitis E. Ketorolac-precipitated asthma. South Med J 1994; 87: 282–4CrossRefGoogle Scholar
  107. 107.
    Hume M, Eddy V. Treatment of chronic obstructive airways obstruction with indomethacin. Scan J Respir Dis 1977: 58: 284–6Google Scholar
  108. 108.
    Nishikawa M, Yoshinaga T, Igarashi A, et al. Clinical experience with indomethacin (Indacin). Shiryo- To-Shiyaku 1966; 3: 1917–20Google Scholar
  109. 109.
    Kordansky D, Adkinson F, Norman PS, et al. Asthma improved by nonsteroidal anti-inflammatory drugs. Ann Intern Med 1978; 88: 508–11PubMedGoogle Scholar
  110. 110.
    Jackson RH, Raymer WJ, Etter RL. New therapy in bronchial asthma: an evaluation of Ponstel (mefanic acid) in chronic bronchial asthma and pulmonary emphysema. J Kansas Med Soc 1969; 69: 474–8Google Scholar
  111. 111.
    Herxheimer H, Stresseman E. Anti-asthmatic effect of phenazone and amidopyrine. Nature 1961; 192: 1089–90PubMedCrossRefGoogle Scholar
  112. 112.
    Hady S. Dipyrone in bronchial asthma [letter]. BMJ 1973; 1: 744PubMedCrossRefGoogle Scholar
  113. 113.
    Streseman E. Die Wirkung von antipyretischen and analgetischensubstanzen auf das menschliche bronchial asthma und das experimentelle Meerschweiche asthma. Acta Allergologica 1963; 18: 211–34Google Scholar
  114. 114.
    Azelastine- Asthma study group. An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. J Allergy Clin Immunol 1996; 97: 1218–24Google Scholar
  115. 115.
    Ben-Noun L. Drug-related asthma. J Pharm Technol 1998; 14: 116–24Google Scholar
  116. 116.
    Sweet JM, Stevenson DD, Simon RA, et al. Long-term effects of aspirin desensitization- treatment for aspirin-sensitive rhinosinusitis-asthma. J Allergy Clin Immunol 1990; 85(Pt 1): 59–65PubMedCrossRefGoogle Scholar
  117. 117.
    Szczeklik A, Mastalerz L, Nizakowska E, et al. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Respir Crit Care Med 1996; 153: 567–71PubMedGoogle Scholar
  118. 118.
    Seth RV, Clarke VS, Lewis RA, et al. Effect of propranolol on the airway response to prostaglandin E2 in normal man. Br J Clin Pharmacol 1981; 12: 731–5PubMedCrossRefGoogle Scholar
  119. 119.
    O’Connor BJ, Fuller RW, Barnes PJ. Nonbronchodilator effects of inhaled beta2-agonists: greater protection against adenosine monophosphate than metacholine -induced bronchoconstriction in asthma. Am J Respir Crit Med 1994; 150: 381–7Google Scholar
  120. 120.
    Szczeklik A. Aspirin-induced asthma. In: Vane JR, Botting RM, editors. Aspirin and other salicylates. New York (NY): Chapman & Hall Medical, 1992: 548–75Google Scholar
  121. 121.
    Sladek KR, Dworski J, Soja JR, et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 1994; 149: 940–6PubMedGoogle Scholar
  122. 122.
    Josefson D. Asthma linked with Churg-Strauss syndrome [letter]. BMJ 1997; 315: 330PubMedGoogle Scholar
  123. 123.
    Christie PE, Smith CM, Lee TH. The potent and selective sulidopeptide leukotriene antagonists, SK and F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991; 144: 957–8PubMedCrossRefGoogle Scholar
  124. 124.
    Dahl R. Oral and inhaled sodium cromoglycate in challenge test with food allergens or acetylsalicylic acid. Allergy 1981; 36: 161–5PubMedCrossRefGoogle Scholar
  125. 125.
    Israel EA, Fischer MA, Rosenberg CM, et al. The pivotal role of lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148: 1447–51PubMedCrossRefGoogle Scholar
  126. 126.
    Szczeklik A, Serwonska M. Inhibition of idiosyncratic reactions to aspirin in asthmatic patients by clemastine. Thorax 1979; 34: 654–7PubMedCrossRefGoogle Scholar
  127. 127.
    Philips GD, Foord R, Holgate ST. Inhaled lysine-aspirin as a bronchoprovocation procedure in aspirin-induced asthma: its repeatability, absence of late-phase reaction and the role of histamine. J Allergy Clin Immunol 1989; 84: 323–41CrossRefGoogle Scholar
  128. 128.
    O’Byrne M. Leukotrienes in the pathogenesis of asthma. Chest 1997; 111: S27–S34CrossRefGoogle Scholar
  129. 129.
    Spector SL, Wangaard CH, Farr RS. Aspirin and concomitant idiosyncrasies in the adult asthmatic patients. J Allergy Clin Immunol 1979; 64: 500–6PubMedCrossRefGoogle Scholar
  130. 130.
    Lipworth BJ. The emerging role of leukotriene antagonists in asthma therapy. Chest 1999; 115: 313–5PubMedCrossRefGoogle Scholar
  131. 131.
    Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist in the treatment of chronic asthma. Arch Int Med 1998 158: 123–20CrossRefGoogle Scholar
  132. 132.
    Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year oldchildren with asthma. J Pediatr 1998 133: 424–8PubMedCrossRefGoogle Scholar
  133. 133.
    Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone and placebo for chronic asthma. Ann Intern Med 1999 130: 487–95PubMedGoogle Scholar
  134. 134.
    Masi At, Hunder GG, Lie JT, et al. The American Colledge of Rheumatology 1990 criteria for the classification of the Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33; 1094–100PubMedCrossRefGoogle Scholar
  135. 135.
    Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998 279: 455–7PubMedCrossRefGoogle Scholar
  136. 136.
    Knoell DL, Lucas J, Allen JN. Churg-Strauss syndrome associated with zafirlukast. Chest 1998; 114: 332–4PubMedCrossRefGoogle Scholar
  137. 137.
    Flower RJ, Moncada S, Vane JR. Analgetic-antipyretic and anti-inflammatory agents; drugs employed in the treatment of gout. In: Gilman AG, Goodman LS, Gilman A, editors. The pharmacological basis of therapeutics. 6th ed. New York (NY): MacMillan, 1980: 682–728Google Scholar
  138. 138.
    Rosenow EC III. Drug-induced pulmonary disease. In:Murray JF, Nadel JA, editors. Textbook of respiratory medicine. Philadelphia (PA): WB Saunders, 1994: 2117–43Google Scholar
  139. 139.
    Smith W, Ball GV. Lung injury due to gold treatment. Arthritis Rheum 1980; 23: 351–4PubMedCrossRefGoogle Scholar
  140. 140.
    Scott DL, Bradgy GVH, Altman TJ, et al. Relationship of gold and penicillamine therapy to diffuse interstitial lung disease. Ann Rheum Dis 1981 40: 136–41PubMedCrossRefGoogle Scholar
  141. 141.
    Ettensohn DB, Roberts NJ, Condemi JJ. Bronchoalveolar lavage in gold lung. Chest 1984; 85: 569–70PubMedCrossRefGoogle Scholar
  142. 142.
    Klassen CD. Heavy metals and heavy-metal antagonists. In: Gilman AG, {Goodman LS}, Gilman A, editors. The pharmacological basis of therapeutics. 6th ed. New York (NY): Macmillan, 1980: 1615–37Google Scholar
  143. 143.
    Stein HB, Patterson AC, Offer RC, et al. Adverse effects of d-penicillamine in rheumatoid arthritis. Ann Intern Med 1980 92: 24–9PubMedGoogle Scholar
  144. 144.
    Lyle WH. D-Penicillamine and fatal obliterative bronchiolitis. BMJ 1977; 1: 105PubMedCrossRefGoogle Scholar
  145. 145.
    Chalmes A, Thompson D, Stein HB, et al. Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis. Ann Intern Med 1982 97: 659–63Google Scholar
  146. 146.
    Cooper JAD, White DA, Matthay RA. Drug-induced pulmonary disease. Part 2: noncytotoxic drugs. Am Rev Respir Dis 1986; 133: 488–505PubMedGoogle Scholar
  147. 147.
    Holmberg L, Boman G, Bottiger LE, et al. Adverse reactions to nitrofurantoin. Analysis of 921 reports. Am J Med 1980; 69; 733–8PubMedCrossRefGoogle Scholar
  148. 148.
    Hailey FJ, Glascock HW, Hewitt WF. Pleuropneumonic reactions to nitrofurantoin. N Engl J Med 1969; 282: 1087–90CrossRefGoogle Scholar
  149. 149.
    Rosenow EC, Martin WJ. Drug-induced interstitial lung disease. In: Schwarz MI, King Jr TE, editors. Interstitial lung disease. Toronto: BC Decker, 1988: 123–37Google Scholar
  150. 150.
    Prakash UBS. Pulmonary reaction to nitrofurantoin. Semin Respir Dis 1980; 2: 71–5Google Scholar
  151. 151.
    Holmberg L, Boman G. Pulmonary reactions to nitrofurantoin. 447 cases reported to the Swedish Adverse Drug Reaction Committee 1966-1976. Eur J Respir Dis 1981; 62: 180–9PubMedGoogle Scholar
  152. 152.
    Dweik RA. Drug-induced pulmonary disease. In: Baum GL, Crapo JD, Celli BR, et al., editors. Textbook of pulmonary diseases. 6th ed. Philadelphia (PA): Lippincott Raven, 1988: 477–90Google Scholar
  153. 153.
    Wang KK, Bowyer BA, Fleming CR, et al. Pulmonary infiltrates and eosinophilia associated with sulphasalazine. Mayo Clin Proc 1984; 59: 343–6PubMedGoogle Scholar
  154. 154.
    Jordan A, Cowan RE. Reversible pulmonary disease and eosinophilia associated with sulphasalazine. J R Soc Med 1988; 81: 233–5PubMedGoogle Scholar
  155. 155.
    Williams T, Eidus L, Thomas P. Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy. Chest 1982; 81: 766–8PubMedCrossRefGoogle Scholar
  156. 156.
    Warner WA, Sanders E. Neuromuscular blockage associated with gentamicin therapy. JAMA 1971; 215: 1153–4PubMedCrossRefGoogle Scholar
  157. 157.
    Dutcher JP, Kendall J, Norris D, et al. Granulocyte transfusion therapy and amphotericin B. Am J Hematol 1989 31: 102–8PubMedCrossRefGoogle Scholar
  158. 158.
    Levine SJ, Walsh TJ, Martinez A, et al. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med 1991 114: 664–6PubMedGoogle Scholar
  159. 159.
    Roncoroni AJ, Corrado C, Besuchio SB, et al. Bronchiolitis obliterans possibly associated with amphotericin [letter]. B J Infect Dis 1990 161: 589CrossRefGoogle Scholar
  160. 160.
    Geahart MO, Bhutani MS. Intravenous pentamidine-induced bronchospasm. Chest 1992; 102: 1891–2CrossRefGoogle Scholar
  161. 161.
    Katzman M, Meade W, Iglar K, et al. High incidence of bronchospasm with regular administration of aerolized pentamidine. Chest 1992; 101: 79–81PubMedCrossRefGoogle Scholar
  162. 162.
    McFadden ER. Obstructive lung disease: anticholinergic agents. In: Branch WT, editor. Office practice of medicine. Philadelphia (PA): WB Saunders, 1987: 315–29Google Scholar
  163. 163.
    Patel KR, Tullet WM. Bronchoconstriction in response to ipratropium bromide. BMJ 1983; 286: 1318PubMedCrossRefGoogle Scholar
  164. 164.
    Beasley CRW, Rafferty P, Holgate ST. Bronchoconstriction properties of preservatives in ipratropium bromide (Aerovent) nebulised solution. BMJ 1987; 294: 1197–8PubMedCrossRefGoogle Scholar
  165. 165.
    Connolly CK. Adverse reaction to ipratropium bromide. BMJ 1982; 294: 1197–8Google Scholar
  166. 166.
    Clark RJ. Exacerbation of asthma after nebulised beclamethasone diproprionate. Lancet 1986; I: 74–5Google Scholar
  167. 167.
    McGivern DV, McFarlane JT. Severe bronchoconstriction after inhalation of budenoside. BMJ 1984; 288: 447PubMedCrossRefGoogle Scholar
  168. 168.
    Shim C, Williams Jr MH. Cough and wheezing from beclamethasone aerosol. Chest 1987; 91: 207–9PubMedCrossRefGoogle Scholar
  169. 169.
    Kounis NG. Untoward reaction to corticosteroids: intolerance to hydrocortisone. Ann Allergy 1976; 36: 203–6PubMedGoogle Scholar
  170. 170.
    Dajani JC, Sliman NA, Shubar KS, et al. Bronchospasm caused by intravenous hydrocortisone sodiumsuccinate (SoluCortef) in aspirin sensitive asthmatics. J Allergy Clin Immunol 1981; 68: 201–4PubMedCrossRefGoogle Scholar
  171. 171.
    Partrige MR, Gibson GL. Adverse bronchial reaction to intravenous hydrocortisone in aspirin-sensitive patients. BMJ 1978; 1: 1521–2CrossRefGoogle Scholar
  172. 172.
    Prophylactic anti-asthma agents. In: Reynolds JEF, editor. Martindale: the extra pharacopoeia. 30th ed. London: The Pharmaceutical Press, 1993: 1140–6Google Scholar
  173. 173.
    Ibanex MD, Laso T, Irineo MM-S, et al. Anaphylaxis to disodium cromoglycate. Ann Allergy Immunol 1996; 77: 185–6CrossRefGoogle Scholar
  174. 174.
    Murphy S, Kelly HW. Cromolyn sodium: a review of mechanisms and clinical use in asthma. Drug Intell Clin Pharm 1987; 21: 22–35PubMedGoogle Scholar
  175. 175.
    Serup J. Severe asthmatic reaction during long-term treatment with disodium cromoglycate powder inhalations. Acta Med Scand 1979; 205: 447–8PubMedCrossRefGoogle Scholar
  176. 176.
    Leynadier F, Pujade-Lauraine MD, Cornaille G. Death after cromoglycate. Allergy 1985; 40: 540–1PubMedCrossRefGoogle Scholar
  177. 177.
    Sheffer AL, Rocklin RE, Goetzi EJ. Immunologic component of hypersensitivity reactions to cromolyn-sodium. N Engl J Med 1975; 293: 1220–4PubMedCrossRefGoogle Scholar
  178. 178.
    Settipane GA, Klein DE, Boyd GK, et al. Adverse reactions to cromolyn. JAMA 1979; 23: 811–3CrossRefGoogle Scholar
  179. 179.
    Skarpaas IJK. An unexpected reaction towards disodium chromoglycate. Allergy 1987; 42: 318–9PubMedCrossRefGoogle Scholar
  180. 180.
    Brown LA, Kaplan RA, Benjamin PA, et al. Immunoglobulin E-mediated anaphylaxis with inhaled cromolyn sodium. J Allergy Immunol 1989; 68: 416–20CrossRefGoogle Scholar
  181. 181.
    Wass U, Plaschke P, Bjorkander J, et al. Assay of specific IgE antibodies to disodium cromoglycate in serum from patients with an immediate hypersensitivity reactions. J Allergy Clin Immunol 1988; 81: 752–7CrossRefGoogle Scholar
  182. 182.
    Allegra L, Bianco S. Non-specific bronchoreactivity obtained with an ultrasonic aerosol of d stilled water. Eur J Respir Dis 1980; 61 Suppl.: S41–S49Google Scholar
  183. 183.
    Sheppard D, Rizk N, Boushey HA, et al. Mechanism of cough and bronchoconstriction induced by distilled water aerosol. Am Rev Respir Dis 1983; 127: 691–4PubMedGoogle Scholar
  184. 184.
    Schoeffel RE, Anderson SD, Altounyan RE. Bronchial hyper-reactivity in response to inhalation of ultrasonically nebulized solutions of distilled water and saline. BMJ 1981; 283: 1285–7PubMedCrossRefGoogle Scholar
  185. 185.
    Nicklas RA. Paradoxical bronchospasm associated with the use of inhaled beta agonists. J Allergy Clin Immunol 1990; 85: 959–64PubMedCrossRefGoogle Scholar
  186. 186.
    Graff-Lonnevig V. Diurnal expiratory flow after inhalation of Freons and fenoterol in childhood asthma. J Allergy Clin Immunol 1979; 64: 534–8PubMedCrossRefGoogle Scholar
  187. 187.
    Sterline GM, Batten JC. Effect of aerosol propellants and surfuctants on airway resistance. Thorax 1969; 24: 226Google Scholar
  188. 188.
    Valic F, Skuvic Z, Bantic Z, et al. Effects of fluorocarbone propellants on respiratory airflow and ECG. Br J Ind Med 1977 34: 130PubMedGoogle Scholar
  189. 189.
    Gong Jr H, Tashkin DP, Calvarese BM. Alcohol-induced bronchospasm in an asthmatic patient: pharmacological evaluation of the mechanism. Chest 1981; 80: 167–73PubMedCrossRefGoogle Scholar
  190. 190.
    Stevenson DD, Simon RA. Sulfites and asthma. J Allergy Clin Immunol 1984; 74: 469–72PubMedCrossRefGoogle Scholar
  191. 191.
    Schwartz HJ, Chester EH. Bronchospastic responses to aerosolised metabisulphite in asthmatic subjects: potential mechanisms and clinical implications. J Allergy Clin Immunol 1984; 74: 511–3PubMedCrossRefGoogle Scholar
  192. 192.
    Anonymous. Nebulisers and paradoxical bronchoconstriction [letter]. Lancet 1988; II: 202Google Scholar
  193. 193.
    Cooper JAD, White DA, Matthay RA. State of the art. Drug induced pulmonary disease. Part I: Cytotoxic drugs. Am Rev Resp Dis 1986; 133: 321–40PubMedGoogle Scholar
  194. 194.
    Rosenow EC, Wilson WR, Cockerill FR. Pulmonary disease in the immunocomprised host. Mayo Clin Proc 1985; 60: 473–87PubMedGoogle Scholar
  195. 195.
    Holoye PY, Luna MA, MacKay B, et al. Bleomycin hypersensitivity pneumonitis. Ann Intern Med 1978 88: 47–9PubMedGoogle Scholar
  196. 196.
    Twohig KL, Mattay RA. Pulmonary effects of cytotoxic agents other than bleomycin. Clin Chest Med 1990; 11: 31–54PubMedGoogle Scholar
  197. 197.
    O’Driscoll BR, Hasleton PS, Taylor PM, et al. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 1990 323: 378–82PubMedCrossRefGoogle Scholar
  198. 198.
    Selker RG, Jacobs SA, Moore PB, et al. 1,3- Bis (2-chloroethyl) — 1 - nitrosourea (BCNU)- induced pulmonary fibrosis. Neurosurgery 1980 7: 760–5Google Scholar
  199. 199.
    Weiss RB, Poster DS, Penta JS. The nitrosoureas and pulmonary toxicity. Cancer Treat Rev 1981; 8: 111–25PubMedCrossRefGoogle Scholar
  200. 200.
    Pascual RS, Mosher MB, Sikand RS, et al. Effects of bleomycin on pulmonary function in man. Am Rev Respir Dis 1975 108: 211–7Google Scholar
  201. 201.
    Ahlgren JD, Smith FP, Kervin DM, et al. Pulmonary disease as a complication of chlorozotocin chemotherapy. Cancer Treat Rep 1981 65: 223–9PubMedGoogle Scholar
  202. 202.
    Yagoda A, Mukherji B, Young C, et al. Bleomycin: an antitumor antibiotic: clinical experience in 274 patients. Ann Intern Med 1972 77: 861–70PubMedGoogle Scholar
  203. 203.
    Brashear RE. Effects of heroin, morphine, methadone, and propoxyphene on the lung. Semin Respir Med 1980; 2: 59–69CrossRefGoogle Scholar
  204. 204.
    Heffner JE, Harley RA, Schabel SI. Pulmonary reactions from illicit substance abuse. Clin Chest Med 1990; 11: 151–62PubMedGoogle Scholar
  205. 205.
    Overland ES, Nolan AJ, Hopewell PC. Alternation of pulmonary function in intravenous drug abusers: prevalence, severity, and characterization of gas exchange abnormalities. Am J Med 1980; 68: 231–7PubMedCrossRefGoogle Scholar
  206. 206.
    Smith WR, Wells JD, Glauser FL, et al. Immunologic abnormalities in heroin lungs. Chest 1975 68: 651–3CrossRefGoogle Scholar
  207. 207.
    O’Donnell AE, Pappas LS. Pulmonary complications of intravenous drug abuse. Experience at an inner-city hospital Chest 1988; 94: 251–3Google Scholar
  208. 208.
    Ettinger L, Albin RJ. A review of the respiratory effects of smoking cocaine. Am J Med 1989; 87: 664–8PubMedCrossRefGoogle Scholar
  209. 209.
    McCarrol KA, Roszler MH. Lung disorders due to drug abuse. J Thorac Imaging 1991; 6: 30–5CrossRefGoogle Scholar
  210. 210.
    Kline JN, Hirasuna JD. Pulmonary edema after free-base cocaine smoking not due to an adulterant. Chest 1990; 97: 1009–10PubMedCrossRefGoogle Scholar
  211. 211.
    Patel RC, Dutta D, Schonfeld SA. Free-base cocaine use associated with bronchiolitis obliterans organizing pneumonia. Ann Intern Med 1987; 107: 186–7PubMedGoogle Scholar
  212. 212.
    Collins E, Hardwick H, Jeffery H. Perinatal cause of cocaine intoxication. Med J Aust 1989; 150: 331–2.PubMedGoogle Scholar
  213. 213.
    Rubin RB, Neugarten J. Cocaine-associated asthma. Am J Med 1990; 88: 438–9PubMedCrossRefGoogle Scholar
  214. 214.
    Forrester JM, Steele AW, Waldron JA. Crack lung: an acute pulmonary syndrome with a spectrum of clinical and histological findings. Am Rev Respir Dis 1990; 142; 462–7PubMedGoogle Scholar
  215. 215.
    Franz DN. Central nervous system stimulants. In: Gilman AG, Goodman LS, Rall TW, et al., editors. The pharmacological basis of therapeutics. 7th ed. New York (NY): Macmillan, 1985: 586–7Google Scholar
  216. 216.
    Parran Jr TV, Jasinski DR. Intravenous methylphenidate abuse. Arch Intern Med 1991; 151: 781–3PubMedCrossRefGoogle Scholar
  217. 217.
    Schmidt RA, Glenny RW, Godwin JD, et al. Panlobular emphysema in young intravenous ritalin abusers. Am Rew Respir Dis 1991; 143: 649–56Google Scholar
  218. 218.
    Mahutte CK, Nakasato SK, Light RW. Haloperidol and sudden death due to pulmonary edema. Arch Intern Med 1982; 142: 1951–2PubMedCrossRefGoogle Scholar
  219. 219.
    Li C, Gefter WB. Acute pulmonary edema induced by overdosage of phenothiazines. Chest 1992; 101: 102–4PubMedCrossRefGoogle Scholar
  220. 220.
    Roy TM, Ossorio MA, Cipola LM, et al. Pulmonary complications of tricyclic antidepressant overdosage. Chest 1989; 96: 852–6PubMedCrossRefGoogle Scholar
  221. 221.
    Varnell RM, Godwin JD, Richardson ML, et al. Adult respiratory distress syndrome from overdose of tricyclic antidepressants. Radiology 1989; 170: 667–70PubMedGoogle Scholar
  222. 222.
    Shannon M, Lovejoy Jr FH. Pulmonary consequences of severe tricyclic anti-depressant ingestion. J Toxicol Clin Toxicol 1989; 25: 443–61CrossRefGoogle Scholar
  223. 223.
    Wilson IC, Gambill JM, Sandifer MG. Loefler’s syndrome occurring during imipramine therapy. Am J Psychiatry 1963; 119: 892–3PubMedGoogle Scholar
  224. 224.
    Cullinan SA, Bower GC. Acute pulmonary hypersensitivity to carbamazepine. Chest 1975; 68: 580–1PubMedCrossRefGoogle Scholar
  225. 225.
    Stephan WC, Parks RD, Tempest B. Acute hypersensitivity pneumonitis associated with carbamazepine therapy. Chest 1978; 74: 463–4PubMedCrossRefGoogle Scholar
  226. 226.
    Ingemarsson I, Arulkumaran S, Kottegota SR. Complications of beta-mimetic therapy in preterm labour. Aust N Z J Obstet Gynaecol 1985; 25: 182–9PubMedCrossRefGoogle Scholar
  227. 227.
    Reed CR, Glauser FL. Drug-induced noncardiogenic pulmonary edema. Chest 1991; 100: 1120–4PubMedCrossRefGoogle Scholar
  228. 228.
    Pisani RJ, Rosenow EC. Pulmonary edema associated with tocolytic therapy. Ann Intern Med 1989; 110: 714–8PubMedGoogle Scholar
  229. 229.
    Eliasson O, Scherzer HH, DeGraff AC. Morbidity in asthma in relation to menstrual cycle. J Allergy Clin Immunol 1986; 77: 87–94PubMedCrossRefGoogle Scholar
  230. 230.
    Gibs CJ, Coutts II, Lock R, et al. Premenstrual exacerbation of asthma. Thorax 1984; 39: 833–6CrossRefGoogle Scholar
  231. 231.
    Derimanov G, Oppenheimer J. Exacerbation of premenstrual asthma caused by oral contraceptive. Ann Allergy Asthma Immunol 1998; 82: 243–6CrossRefGoogle Scholar
  232. 232.
    Tan KS, McFarlane LC, Lipworth BJ. Paradoxical down-regulation and desensitization of beta 2-adrenoreceptors by exogenous progesterone in female asthmatics. Chest 1997; 111: 847–51PubMedCrossRefGoogle Scholar
  233. 233.
    Tan KS, McFalane LC, Lipworth BJ. Loss of normal cyclical beta 2-adrenoreceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients. Thorax 1997; 52: 608–11PubMedCrossRefGoogle Scholar
  234. 234.
    Tan KS, McFarlane LC, Lipworth BJ. Modulation of airway reactivity and peak flow variability in asthmatics receiving the oral contraceptive pill. Am J Respir Crit Care Med 1997; 155: 1273–7PubMedGoogle Scholar
  235. 235.
    Troisi RJ, Speizer FE, Willett WC, et al. Menopause, postmenopausal estrogen preparations, and the risk of adult onset asthma. Am J Respir Crit Care Med 1995; 152: 1183–8PubMedGoogle Scholar
  236. 236.
    Kinnunen E, Viljanen A. Pleuropulmonary involvement during bromocriptine treatment. Chest 1988; 94: 1034–3PubMedCrossRefGoogle Scholar
  237. 237.
    McElvaney NG, Wilcox PG, Churg A, et al. Pleuropulmonary disease during bromocriptine treatment of Parkinson’s disease. Arch Intern Med 1988; 148: 2231–6PubMedCrossRefGoogle Scholar
  238. 238.
    Hindle W, Posner E, Sweetnam MMT, et al. Pleural effusion and fibrosis during treatment with methysergine. BMJ 1970 6: 83–102Google Scholar
  239. 239.
    Rubin LJ. Primary pulmonary hypertension. Chest 1993; 104: 236–50PubMedCrossRefGoogle Scholar
  240. 240.
    Rich S, Danzker DR, Ayrer SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987 107: 216–23PubMedGoogle Scholar
  241. 241.
    Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996 335: 609–16PubMedCrossRefGoogle Scholar
  242. 242.
    Hadengue A, Benhayoun MK, Lebree D, et al. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991 100: 520–8PubMedGoogle Scholar
  243. 243.
    McDonnell PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983; 127: 437–41PubMedGoogle Scholar
  244. 244.
    Kleiger RE, Boxer M, Ingham RE, et al. Pulmonary hypertension in patients using oral contraceptives: a report of six cases. Chest 1976; 69: 143–7PubMedCrossRefGoogle Scholar
  245. 245.
    Masi AT. Pulmonary hypertension and oral contraceptive usage. Chest 1976; 69: 451–3PubMedCrossRefGoogle Scholar
  246. 246.
    Legoux B, Piette AM, Boucher PE, et al. Pulmonary hypertension and HIV infection. Am J Med 1990 89: 122PubMedCrossRefGoogle Scholar
  247. 247.
    Londino A Jr V, Wolf GL, Calabro JJ, et al. Naproxen and pneumonitis [letter]. JAMA 1984; 252: 1853PubMedCrossRefGoogle Scholar
  248. 248.
    Antineoplastic agents and immunosuppressants. In: Reynolds JEF, editor. Martindale: the extra pharmacopoeia. 30th edition. London: The Pharmaceutical Press, 1993: 434–507Google Scholar
  249. 249.
    Cherniac RM, Abrams J, Kalica AR. Pulmonary disease associated with breast cancer therapy. J Respir Crit Care Med 1994; 150: 1169–73Google Scholar
  250. 250.
    Cohen MB, Austin JHM, Smith-Vaniz A, et al. Single case reports. Nodular bleomycin toxicity. Am J Clin Pathol 1989 92: 101–4PubMedGoogle Scholar
  251. 251.
    Santrach PL, Askin FB, Wells RJ, et al. Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer 1989 64: 806–11PubMedCrossRefGoogle Scholar
  252. 252.
    Rao SX, Ramaswamy G, Levin M, et al. Fatal acute respiratory failure after vinblastine-mitomycin therapy in lung carcinoma. Arch Intern Med 1985 145: 1906–7Google Scholar
  253. 253.
    Hoelzer KL, Harrison BR, Luedke SW, et al. Vinblastine-associated pulmonary toxicity in patients receiving combination therapy with mitomycin and cisplatin. Drug Intell Clin Pharm 1986 20: 287–9PubMedGoogle Scholar
  254. 254.
    Bellamy EA, Husband JE, Blaquiere RM, et al. Bleomycin-related lung damage: CT evidence. Radiology 1985 156: 155–8PubMedGoogle Scholar
  255. 255.
    Min K-W, Gyorkey FI. Interstitial pulmonary fibrosis, atypical epithelial changes and bronchiolar cell carcinoma following busulfan therapy. Cancer 1968; 22: 1027–32PubMedCrossRefGoogle Scholar
  256. 256.
    Aymard JP, Gyger M, Lavallee R, et al. A case of pulmonary alveolar proteinosis complicating chronic myelogenous leukemia. A peculiar pathologic aspect of busulfan lung? Cancer 1984; 53: 954–6PubMedCrossRefGoogle Scholar
  257. 257.
    Sostman HD, Matthay RA, Putman CE. Cytotoxic drug-induced lung disease. Am J Med 1977; 62: 608–15PubMedCrossRefGoogle Scholar
  258. 258.
    Durant JR, Norgard MJ, Murad TM, et al. Pulmonary toxicity associated with bischloroethyl nitrosourea (BCNU). Ann Intern Med 1979 90: 191–4PubMedGoogle Scholar
  259. 259.
    Kuplic JB, Higley CS, Niewoehner DE. Pulmonary ossification associated with long-term busulfan therapy in chronic myeloid leukemia. Am Rev Respir Dis 1972; 106: 759–62PubMedGoogle Scholar
  260. 260.
    Stolley PD, Tonascia JA, Tockman MS, et al. Thrombosis with low-estrogen oral contraceptives. Am J Epidemiol 1975 102: 197–208PubMedGoogle Scholar
  261. 261.
    Wright DG, Robichaud KJ, Pizzo PA, et al. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med 1981 304: 1185–9PubMedCrossRefGoogle Scholar
  262. 262.
    Davies D, MacFarlane A. Fibrosing alveolitis and treatment with sulphasalazine. Gut 1974; 15: 185–8PubMedCrossRefGoogle Scholar
  263. 263.
    Tydd TF, Dyer NH. Sulphasalazine lung. Med J Aust 1976; 1: 570–1PubMedGoogle Scholar
  264. 264.
    Sternlieb I, Bennet B, Scheinberg IH. D-penicillamine induced Goodpasture’s syndrome in Wilson’s disease. Ann Intern Med 1975; 82: 673–6PubMedGoogle Scholar
  265. 265.
    Shesser R, Davis C, Edeldtein S. Pneumomediastinum and pneumothorax after inhaling alkyloid cocaine. Ann Emerg Med 1982; 10: 213–5CrossRefGoogle Scholar
  266. 266.
    Morris JB, Shock JM. Pneumomediastinum in a young male cocaine user. Ann Emerg Med 1985; 14: 264–6CrossRefGoogle Scholar
  267. 267.
    Murray JB, Smialek J, Golle M, et al. Pulmonary vascular abnormalities in cocaine users. Am Rev Respir Dis 1988; 137Suppl. 4 (P22): 459Google Scholar
  268. 268.
    Alfred RJ, Ewer S. Fatal pulmonary edema following intravenous ‘freebase’cocaine use. Ann Emerg Med 1981; 10: 441–2CrossRefGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  • Liubov (Louba) Ben-Noun
    • 1
  1. 1.Ben-Gurion University of the Negev, Faculty for Health Sciences, Department of Family MedicineKiryat-GatIsrael

Personalised recommendations